

Drug Monograph

Drug Name: **Duaklir® Pressair® (aclidinium bromide and formoterol fumarate) 400 mcg/12 mcg Inhalation Powder**
 Drug Class: **Anticholinergics, Long-Acting Beta Agonist (LABA) Combination Agents**
 Prepared For: MO HealthNet
 Prepared By: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Duaklir Pressair is a dry powder inhaler containing 400 mcg of aclidinium bromide and 12 mcg formoterol fumarate per actuation.

Manufacturer: Manufactured for: Circassia Pharmaceuticals, Inc., Morrisville, NC 27560.

Indications: Duaklir Pressair is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Costs: \$995 per inhaler (60 metered doses). Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List (PDL) as non-preferred.

Status Recommendation: Prior Authorization (PA) Required Open Access
 Fiscal Edit PDL

Type of PA Criteria: Increased Risk of ADE Preferred
 Appropriate Indications Non-Preferred

Prepared By: Jennifer Anderson PharmD, BCPS
 Date: November 10, 2019